Table 3.
Summary results of NGS and IHC biomarker analysis
| Pt | Tissue | DNAseq | IHC | Clinical test results | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of coding SNV | No of unique SNV | Oncogene | CHIP mutation |
PD‐L1 (E1L3N) TPS (%) |
PD‐L1 (28‐8) TPS (%) | CD8 | Ki67 | CD31 | |||
| 1 | Left lung | 14 | 1 | KRAS G12V 14% | JAK2 E558N 47% | 55 | 85 | High | Low | 43.3 | Not evaluated |
| Right lung | 21 | 1 | KRAS G12V 41% | JAK2 E558N 55% | 40 | 40 | Med | Low | 27.3 | ||
| Mediastinal lymph node | 21 | 1 | KRAS G12V 19% | JAK2 E558N 46% | 70 | 90 | Mod | Low | 27.3 | ||
| Liver | 20 | 0 | KRAS G12V 51% | JAK2 E558N 48% | 70 | 95 | Med | Low | 34.0 | ||
| 3 | Lung right lower lobe | 12 | 1 | KRAS G12V 55% | TET2 P1723S 57% | 0 | 0 | High | Med | 29.7 | Not evaluated |
| Lung right upper lobe | 14 | 2 | KRAS G12V 49% | TET2 P1723S 41% | 0 | 0 | Med | Low | 91.7 | ||
| 4 | Right lung | 16 | 2 | KEAP1 E441* 87%, TP53 N239D 80% | 0 | 0 | Low | high | 34.7 | Not evaluated | |
| Pericardial lymph node | 13 | 0 | TP53 N239D 79% | 10 | 0 | Med | high | 52.3 | |||
| Liver | 15 | 2 | KEAP1 E441* 45%, TP53 N239D 41% | 0 | 0 | Low | High | 24.7 | |||
| 6 | Lung left lower lobe | 7 | 1 | BRCA2 R2034C 50%, KRAS G12D 3% | 95 | 95 | High | Med | 34.7 | KRAS‐G12D positive, EML4-ALK negative, EGFR negative | |
| Lymph node | 20 | 14 | BRCA2 R2034C 44%, KRAS G12D 10% | 40 | 70 | High | Low | 32.7 | |||
| 7 | Lung left hilar | 10 | 1 | SMARCA4 R1135Q 13%, EML4-ALK 2.8% | 40 | 60 | High | Low | 27.3 | EML4-ALK positive, EGFR negative, PD‐L1 positive | |
| Mediastinal lymph node | 9 | 0 | SMARCA4 R1135Q 6%, EML4-ALK 2.7% | 70 | 90 | High | Med | 14.7 | |||
Abbreviations: IHC, immunohistochemistry; NGS, next‐generation sequencing; SNV, single‐nucleotide variant; CHIP, clonal hematopoiesis of indeterminate potential; PD‐L1, programmed death ligand 1; TPC, tumor proportion score.